I-Molnupiravir (EIDD-2801) CAS 2349386-89-4 COVID-19 API Umgangatho oPhezulu
Ubonelelo ngezoRhwebo i-Molnupiravir kunye neMidiya eNxulumene nayo enoMgangatho oPhezulu
Uridine CAS 58-96-8
Cytidine CAS 65-46-3
I-Molnupiravir N-1 CAS 2346620-55-9
I-Molnupiravir (EIDD-2801) CAS 2349386-89-4
| Igama leMchiza | I-Molnupiravir (EIDD-2801) |
| Izithethantonye | MK-4482;β-D-N4-Hydroxycytidine-5′-isopropyl ester;((2R,3S,4R,5R)-3,4-dihydroxy-5-((E)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2 -yl) methyl isobutyrate |
| Inombolo yeCAS | 2349386-89-4 |
| Inombolo yeCAT | RF-API97 |
| Ubume beStokhwe | Kwi-Stock, iMveliso yeMveliso ukuya kumakhulu eeKilogram |
| Ifomula yeemolekyuli | C13H19N3O7 |
| Ubunzima beMolekyuli | 329.31 |
| Ukunyibilika | Inyibilika kwi-DMSO |
| Uphawu | Ruifu Chemical |
| Into | Iinkcukacha |
| Imbonakalo | Mhlophe ukuya kwi-Off-White Powder |
| Ukuchongwa kwe-IR | Isampulu yeSpectrum ihambelana naleyo yomgangatho wereferensi |
| Ukuchongwa kwe-HPLC | Ixesha lokugcinwa kwencopho enkulu yesisombululo sesampulu sihambelana nesisombululo esiqhelekileyo |
| Izinto ezinxulumeneyo | |
| Ukungcola A | ≤0.15% |
| Ukungcola B | ≤0.15% |
| Nakuphi na Ukungcola Okungachazwanga | ≤0.15% |
| Ukungcola okungachazwanga ngokupheleleyo | ≤0.30% |
| Ukungcola ngokupheleleyo | ≤0.50% |
| Izinyibilikisi ezishiyekileyo | |
| N-Heptane | ≤5000ppm |
| I-Ethanol | ≤5000ppm |
| Isopropyl Acetate | ≤5000ppm |
| Acetonitrile | ≤410ppm |
| I-Methylene Dichloride | ≤600ppm |
| I-acetone | ≤5000ppm |
| Isopropanol | ≤5000ppm |
| Isiqulatho samanzi (KF) | ≤0.50% |
| Intsalela kwi-Ignition | ≤0.10% |
| Ukujikeleziswa kwe-Optical | -7.5° ukuya -9.5° (C=0.5, iMethanol) |
| Iintsimbi ezinzima | ≤10ppm |
| Ubunyulu / Indlela yokuHlalutya | ≥99.5% (230nm) |
| Indlela yoVavanyo / yoHlahlelo | 98.0% ~ 102.0% (HPLC kwisiseko esomisiweyo) |
| Beka ubomi kwishelufa | Iinyanga ezingama-24 |
| Umgangatho woVavanyo | Umgangatho woShishino |
| Ukusetyenziswa | API, Molnupiravir (EIDD-2801) COVID-19 Inhibitor |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, igubu lekhadibhodi, 25kg/Igubu, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ekukhanyeni, ukufuma kunye nokuhlaselwa zizinambuzane.
I-Molnupiravir (EIDD-2801, MK-4482) yimveliso yomlomo ye-bioavailable ye-ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) kunye nomsebenzi we-antiviral obanzi ngokuchasene ne-SARS-CoV-2, i-MERS-CoV, I-SARS-CoV, kunye ne-arhente ebangela i-COVID-19.IMolnupiravir ithengiswa phantsi kwegama lebrendi iLagevrio kwaye ngokubanzi njenge-emorivir.I-Molnupiravir ibonakaliswe ukuba iphucula ukusebenza kwemiphunga, yehlisa ukwehla kobunzima bomzimba kunye nokunciphisa umthamo wentsholongwane emiphungeni.Ukongeza kumsebenzi ochasene ne-coronavirus, i-Molnupiravir, kwizifundo zaselabhoratri, ibonakalise umsebenzi ngokuchasene nomkhuhlane wexesha kunye nomkhuhlane weentaka, intsholongwane yokuphefumla ye-syncytial, intsholongwane ye-chikungunya, intsholongwane ye-Ebola, intsholongwane ye-equine encephalitis yaseVenezuela, kunye nentsholongwane yaseMpuma ye-equine encephalitis.I-Molnupiravir ekuqaleni yayiphuhliselwe ukunyanga umkhuhlane kwiDyunivesithi yase-Emory yinkampani yeyunivesithi yokuvelisa amachiza, iDrug Innovation Ventures e-Emory (DRIVE), kodwa kuxelwe ukuba iyekwa ngenxa yeenkxalabo zokuguquka kwezinto.Yathi ke yafunyanwa yinkampani esekwe eMiami iRidgeback Biotherapeutics, eyathi kamva yasebenzisana noMerck & Co. ukuphuhlisa ichiza ngakumbi.I-Molnupiravir yamkelwa ukuba isetyenziswe kwezonyango e-United Kingdom ngoNovemba ka-2021.
